|[June 13, 2013]
Arrowhead to Present at Upcoming Scientific Conferences
PASADENA, Calif. --(Business Wire)--
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics
company, today announced that the company will present data on the
Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520
hepatitis B drug candidate at three upcoming scientific conferences.
Scheduled conference presentations in June include the following:
The 18th Annual Meeting of the RNA Society - Davos, Switzerland,
June 14, 2013
A workshop presentation titled, "Development of Dynamic
Polyconjugates for tissue-targeted delivery of siRNA," will be
presented by Christine Wooddell, Ph.D., Senior Scientist;
4th RNAi Research & Therapeutics Conference - San Francisco,
CA (News - Alert), USA, June 21, 2013
A featured presentation titled, "DPC Technology for siRNA Delivery:
Moving from Platform to Pipeline," will be presented by David Lewis,
Ph.D., Vice President, Biology;
The European CLINAM and ETPN Summit, Clinical Nanomedicine and
Targeted Medicine - Basel, Switzerland, June 26, 2013
An oral presentation titled, "A Novel Hepatitis B Treatment with RNAi,"
will be presented by Christopher Anzalone, Ph.D., President and CEO.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics
company with development programs in oncology, obesity, and chronic
hepatitis B virus. The company is leveraging its platform technologies
to design and develop peptide-drug conjugates (PDCs) that specifically
home to cell types of interest while sparing off-target tissues, create
targeted drugs based on the gene silencing RNA interference (RNAi)
mechanism, and work with partners to create improved versions of
traditional small molecule drugs.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter (News - Alert) @ArrowRes.
To be added to the Company's email list to receive news directly, please
send an email to firstname.lastname@example.org
[ InfoTech Spotlight's Homepage ]